SEC-registered broker-dealer running the Aurora Alternative Trading System for securities finance now backed by two of the largest institutions at the center of U.S. markets, Charles Schwab and DTCC.

Key points

• Provable Markets is modernizing securities finance infrastructure through end to end pre-trade, execution, and post-trade solutions for securities finance.
• Series B funding round led by Charles Schwab, with participation by DTCC, existing investors Dialectic Capital Management, Inkef and others.
• The round supports team growth across all facets, further core market infrastructure connectivity, product and geographical expansion.

NEW YORK, July 29, 2026 — Provable Markets, operator of the securities finance platform Aurora, today announced the completion of its Series B investment round led by Charles Schwab (NYSE: SCHW), with The Depository Trust & Clearing Corporation (DTCC) joining as a new investor, and participation from existing investors Dialectic Capital Management, Inkef and others. 

The investment comes at a pivotal time in the Provable Markets growth story. The platform has posted new records for four consecutive quarters on its ATS processing over $30 trillion in monthly order volume.

“At Schwab, we value supporting innovative firms and technology that strengthen the financial services ecosystem and enable Schwab to meet the needs of our clients,” said Howie Kennedy, Managing Director, Securities Lending, Charles Schwab Corporation. “Provable Markets supports that objective by helping modernize securities finance workflows through automation, connectivity, and scalable solutions, improving capital market efficiency and execution quality.”

Provable Markets facilitates end- to- end securities finance workflows through a fully cloud-native offering that boasts deep connectivity into the heart of the US capital markets infrastructure with connectivity to DTCC’s clearing agency subsidiaries, National Securities Clearing Corporation (NSCC) and The Depository Trust Company (DTC), the OCC, and Tri-party Agents. The platform leverages a novel matching engine within its SEC-registered Alternative Trading System (ATS) that provides clients with increased trade automation on a neutral playing field. With a seamless hand off to its Aurora post-trade solution, Provable eliminates historical bottlenecks that cannot be fixed through front-end workflow solutions alone in this highly complex ecosystem. Coupled with access to NSCC’s SFT Clearing Service, clients can simultaneously realize significant capital relief under Basel regulatory frameworks to generate further ROI for their businesses and expand their trading opportunities.

— Brian Steele, Managing Director, President, Clearing & Securities Services at DTCC, stated, “As demand for securities financing transactions continues to grow, market participants are increasingly seeking solutions that improve capital efficiency while reducing operational complexity. Provable Markets’ integration with DTCC’s SFT Clearing Service helps participants streamline post-trade processing and unlock the balance sheet benefits of central clearing. By supporting and connecting to innovative platforms like Provable, we are helping create a more efficient and scalable securities finance ecosystem that can support continued growth across the market.”

The Series B round will help Provable grow its commercial, product and engineering headcount to support the rapid growth of its client base and related services, while maintaining its level of market leading client service and scalable technology design and architecture. The funds will also drive additional product and geographical expansion.

“We started Provable Markets with the belief that modernizing securities finance is a market structure story that requires a foundational pipes and plumbing approach to rebuild core infrastructure from the bottom up. By maintaining that focus, we have been able to solve real problems for our clients that not only drive scaled automation, but also alleviate the increasingly acute pressures of operational and regulatory capital constraints. Charles Schwab and DTCC’s investment validate and fuels our next stage of growth to execute on our vision of becoming core market infrastructure for the rapidly expanding securities finance landscape and beyond.”— Matt Cohen, Co-Founder & CEO, Provable Markets

ABOUT PROVABLE MARKETS

Provable Markets is driving market structure change, offering front-to-back trade, lifecycle management, and post-trade solutions for cleared and uncleared SFTs — delivering execution optimization, operational efficiency, cost reduction, and risk mitigation across the value chain. Provable Markets is a FINRA member broker-dealer and SIPC member, and market operator of Aurora, a cloud-native alternative trading system (ATS) regulated by the US Securities and Exchange Commission. For more information, visit provablemarkets.com or contact [email protected]. 

SOURCE Provable Markets LLC

PORTLAND, Ore., July 29, 2026 — Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace’s Series A financing round with additional investors expected to join.

Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surgery, including nerves that are otherwise obscured from view by surrounding tissue. The technology enables two clinically significant applications. First, by rendering nerves visible in real time, it allows surgeons to identify and avoid nerves that would otherwise be obscured from view during a broad range of surgical procedures. Second, in cases where a nerve has already been injured, it allows surgeons to localize and assess the nerve with greater precision, supporting more effective surgical repair. Trace’s lead candidate, Nerve Trace Dx, received FDA clearance of its Investigational New Drug (IND) application in December 2025 and has began its Phase I clinical trial evaluating Nerve Trace’s safety and feasibility in surgical patients. Proceeds from the investment will support Trace’s Phase II and III clinical trials toward a New Drug Application (NDA).

“We’re pleased to welcome Axogen, a company that shares our commitment to protecting nerve function, as a strategic partner in this next phase of our growth. This investment strengthens our ability to advance Nerve Trace through the clinical work ahead, giving surgeons visibility into nerves they’ve not been able to see before,” said Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences.

“Improving nerve care starts with being able to see the nerve. You can’t treat what you can’t see,” said Michael Dale, President and CEO of Axogen, Inc. “This investment in Trace’s technology is directly aligned with our mission of making restoration of peripheral nerve function an expected standard of care. Giving surgeons the ability to see nerves in real time, whether to protect them or to treat them, is foundational to that mission.”

About Trace Biosciences

Trace Biosciences is a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, Trace is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings. The company’s mission is to make safe, precise surgery a reality by making nerves visible in every operating room.

For more information, visit www.trace-bio.com 

About Axogen, Inc

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com 

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the terms and expected timing of the financing, the use of proceeds, the progress of clinical trials, and the anticipated benefits of the collaboration between Trace Biosciences and Axogen. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Trace Biosciences undertakes no obligation to update these statements except as required by law.

Media Contact: [email protected] 

SOURCE Trace Biosciences

New platform makes the entire fund administration process visible, auditable, and collaborative – for both sides of the relationship – in real time

STAMFORD, Conn., July 29, 2026 — 4Pines Fund Services today announced the release of the next generation of C2P, a major evolution of its proprietary platform that introduces a fully connected, shared operating environment for fund administration. For the first time, every piece of work, from initial email request through final deliverable, moves through a single system that is visible to both the administrator and the client simultaneously.

The announcement marks a meaningful shift in how 4Pines defines fund administration. Rather than a service performed behind the scenes and reported on after the fact, C2P positions the administrator-client relationship as a shared operating model, one where both teams work in the same environment, with the same view of every task, every status, and every outstanding item in real time.

“C2P has been part of our platform for some time, but what we are announcing today is a major evolution,” said Mike Trinkaus, CEO, 4Pines Fund Services. “For the first time, the entire fund administration process, from email to final report, is happening inside one fully connected, visible, and auditable system. And rather than imposing rigidity as the price of that structure, this generation meets each firm where it is and adapts as it scales. That changes how work gets done, how clients experience it, and how firms grow.”

Fund administration has historically relied on a combination of accounting platforms, spreadsheets, and email-driven workflows that vary by firm. The results have been serviceable, but the process itself has remained largely invisible. Status updates require follow-up. Workflows span disconnected systems. Audit trails are assembled after the fact rather than built in real time. Clients are kept at arm’s length from work that directly affects their investors.

The new generation of C2P addresses this by introducing a shared operating layer that sits above existing systems, agnostic to the accounting platforms, GL systems, and reporting tools a firm already uses, and unifies tasks, communications, approvals, and reporting into one continuous workflow visible to both sides.

At the core of the release is a connected workflow model in which emails are captured in a shared inbox, converted into structured tasks, and managed within defined workflows that drive validation, approvals, and final deliverables. Every request is owned, tracked, and visible from the moment it enters the system to the moment it is resolved. Communication is no longer a parallel channel, it becomes the starting point for execution, with every interaction structured, assigned, and auditable.

Validation, which has historically depended on manual spreadsheets and offline reconciliation, is now embedded directly into the workflow. Validations are built into the workflow, tied to underlying data, and executed as part of the process rather than layered on top of it. Every action within the platform is captured continuously, creating a complete audit trail that includes task ownership, approvals, communications, and supporting documentation, without requiring anyone to reconstruct it after the fact.

Alongside these workflow advances, 4Pines is introducing Acorn, an templated based AI assistant built directly into C2P. Unlike general-purpose AI tools, Acorn operates entirely within each firm’s own environment and data, drawing on live financial data from connected systems, project history, inbox correspondence, and fund documentation to answer questions in plain English. Acorn can not only respond to queries about fund status, capital positions, investor capital-account detail, and project progress in real time, it also provides ad hoc reporting, automated flow creation, data table ingestion and an AI knowledgebase for everyone. Acorn also assists with drafting responses to investor inquiries informed by prior correspondence within the firm’s environment. New Acorn capabilities are being released on an ongoing basis, with the roadmap including automated financial and transactional deliverables, deeper financial data queries, and a fully configurable operational reporting layer built on live fund data.

C2P is designed to operate across existing infrastructure rather than replace it. Firms can connect multiple platforms, standardize workflows across funds, and scale operations without disrupting their current systems. The platform supports any service configuration, full outsourcing, co-sourcing, or self-administered, and connects directly to a client’s own accounting platform instance where applicable.

With this release, 4Pines Fund Services introduces a new standard for what fund administration can look like, not a black box that delivers results, but a shared operating environment where both sides of the relationship can see exactly what is happening, at every step, in real time.

The new generation of C2P is being introduced to 4Pines clients with a process that commenced in June 2026, with additional capabilities rolling out on a continuous basis.

About 4Pines Fund Services

4Pines Fund Services is an employee-owned fund administrator providing fund accounting, operational support, and technology-driven administration to private equity, venture capital, and alternative investment firms. The firm operates as a genuine partner to its clients, 100% U.S.-based, and built around a model of transparency and shared process. C2P is 4Pines’ proprietary client collaboration platform, and the operating foundation of every client relationship the firm manages.

For more information, visit 4PinesFS.com.

Chris Gale, [email protected]

SOURCE 4Pines Fund Services

Financing will help meet growing demand for faster PFAS data across field and laboratory workflows

LONGMONT, Colo., July 29, 2026 — Biota Inc., an environmental diagnostics company developing faster technologies for per- and polyfluoroalkyl substances (PFAS) testing, today announced that it has closed a $3 million seed financing led by Burnt Island Ventures, with significant participation from DeepWork Capital. The round also included renewed participation from Antler, which led Biota’s previous financing, as well as Beyond Utility Water Ventures and the Deming Center Venture Fund.

PFAS are a large family of synthetic chemicals used since the 1940s to make products resistant to heat, oil, stains, grease and water. Known as “forever chemicals,” they do not easily break down, persist in soil and water, and can accumulate in the human body. Exposure to certain PFAS has been linked to liver and immune-system effects, pregnancy complications and some cancers.

“The technology to treat PFAS is advancing, but the ability to measure it has not kept pace,” said Rose Nash, PhD, founder and CEO of Biota. “Organizations cannot optimize treatment systems, map contamination or make rapid remediation decisions when critical data takes weeks to arrive. This financing gives us the capital and strategic partners to bring faster testing tools to the organizations doing the hard work of PFAS monitoring and remediation. I am deeply grateful to our earliest investors, the new investors joining us and the extraordinary Biota team that brought us to this moment. Now, we get to work.”

Biota’s platform accelerates PFAS analysis across both field and laboratory workflows. RapidTest™ is a rapid screening platform designed to provide results in approximately 15 minutes. MagnaPrep™ uses proprietary magnetic nanoparticle technology to streamline laboratory sample preparation.

“The scale of the PFAS challenge will require fundamentally faster and more distributed testing infrastructure,” said Tom Ferguson, Founder and Managing Partner at Burnt Island Ventures. “Rose and the Biota team combine exceptional scientific capability with a firsthand understanding of the analytical bottlenecks slowing the market. We believe Biota can become a critical enabling platform for the PFAS treatment and remediation industry.”

“Biota is addressing a rapidly growing market need with technology that could transform how PFAS contamination is measured and ultimately remediated,” said Benjamin Patz, Managing Partner at DeepWork Capital. “The company has assembled an exceptional team, and we are excited to support Biota as it brings faster, more actionable PFAS testing to market.”

The financing will help scale sales and customer operations, continued advancement of Biota’s rapid PFAS testing tools and expansion of its environmental diagnostics platform to additional contaminants, including microplastics.

Biota recently opened a 7,500-square-foot laboratory and innovation center in Longmont, Colorado, supporting product development, manufacturing and customer deployments.

Biota has received support from the National Institutes of Health’s National Institute of Environmental Health Sciences and the State of Colorado’s Advanced Industries Program. The company also participates in gener8tor’s Great Lakes Innovation Accelerator, supported by the National Oceanic and Atmospheric Administration (NOAA) and the Department of Commerce, and Imagine H2O’s global water innovation ecosystem.

To learn more about Biota and its PFAS testing platform, visit www.biota-labs.com.

About Biota

Biota is an environmental diagnostics company developing faster technologies for PFAS monitoring and analysis. The company’s platform combines rapid screening with innovative laboratory sample preparation technologies to help organizations generate more timely and actionable environmental data. Biota is headquartered in Longmont, Colorado.

About Burnt Island Ventures

Burnt Island Ventures is a specialist venture capital firm investing in entrepreneurs building technologies and businesses for the water sector. The firm supports companies addressing critical water challenges through technology, innovation and scalable business models.

About DeepWork Capital

DeepWork Capital is an early-stage venture capital firm founded in 2015 in Orlando, Florida. The firm invests in tech-forward founders addressing the world’s biggest problems in the technology and life sciences sectors, with a focus on underserved venture capital markets. Learn more at deepworkcapital.com.

Media Contact

Rose Nash, PhD
Founder and CEO
Biota Inc.
[email protected] 
www.biota-labs.com 

SOURCE Biota Inc.

Leading lawsuit funding provider rolls out first-ever national plan to assist victims of cyber-fraud connected to Crypto Currency cases so victims have flexible capital while they wait for justice. 

JERSEY CITY, N.J., July 29, 2026 — Legal Bay LLC, a national leader in pre settlement funding, commercial litigation funding, lawsuit funding, and legal funding, announced today the expansion of its financial services with the launch of cryptocurrency-based funding solutions. The new offering reflects the company’s continued commitment to developing innovative financing products that address the evolving needs of today’s consumers, investors, and businesses.

As cryptocurrency ownership continues to grow and digital assets become an increasingly important part of many individuals’ financial portfolios, Legal Bay recognizes the demand for financing options that provide access to capital without requiring clients to immediately liquidate their cryptocurrency holdings. The company’s crypto-friendly funding program is designed to offer qualified applicants greater financial flexibility while preserving the potential long-term value of their digital assets that may be tied up in court battles.

Chris Janish, CEO of Legal Bay, says, “As financial markets continue to evolve, so do the needs of our clients. Cryptocurrency has become an increasingly important asset class, and we’re committed to staying ahead of financial trends by offering innovative funding solutions that provide greater flexibility and access to capital in fraud lawsuits. We believe we are the first and most experienced company to evaluate and fund crypto cases nationwide. Our company remains focused on delivering responsive service, transparent terms, and funding solutions that adapt to today’s marketplace.”

If you’re a lawyer or plaintiff involved in an active lawsuit and need an immediate cash advance against an impending lawsuit settlement, or if you have been a victim of cyber fraud or cryptocurrency piracy and need legal help, call us and we can put you in touch with the top cryptocurrency fraud lawyers and law firms nationwide.  Please visit Legal Bay HERE or call toll-free at 877.571.0405.

The introduction of cryptocurrency-based advances further expands Legal Bay’s growing portfolio of financial products, which already includes pre settlement funding, lawsuit funding, commercial litigation funding, legal funding, and other specialty financing solutions designed to meet the needs of plaintiffs, law firms, businesses, and individuals facing unique financial circumstances.

Legal Bay notes that cryptocurrency-backed funding represents another step in the company’s broader mission of expanding financial opportunities for clients who may not fit traditional lending models. By combining experienced underwriting with responsive customer service, Legal Bay continues to develop financing programs that address emerging market demands while maintaining prudent risk management standards.

Applications for cryptocurrency-based funding are individually reviewed through Legal Bay’s underwriting process. Funding decisions are based upon eligibility, collateral evaluation, and overall risk assessment, with each application receiving a free comprehensive review of merits of your case before approval.

Legal Bay has built its reputation on providing efficient funding solutions with straightforward communication, competitive pricing, and fast turnaround times. Qualified applicants can often receive funding decisions within 24-48 hours after the necessary documentation has been submitted, allowing clients to access capital when they need it most.

If you’re a lawyer or plaintiff involved in an active lawsuit and need an immediate cash advance against an impending lawsuit settlement, please visit Legal Bay HERE or call toll-free at 877.571.0405.

In addition to cryptocurrency-based advances, Legal Bay continues to offer pre settlement funding, commercial litigation funding, lawsuit funding, legal funding, settlement funding, loans on lawsuits, loans on lawsuit, and loan on lawsuit programs for qualified plaintiffs, law firms, and commercial litigation clients nationwide.

To learn more about Legal Bay’s new cryptocurrency-based funding solutions, commercial litigation funding, or other financing programs, please visit Legal Bay HERE or call toll-free: 877.571.0405 where agents are standing by.

Contact: Chris Janish, CEO

     Email:  info@Legal Bay.com 
     Ph.: 877.571.0405
     Website: www.Legal Bay.com 

Follow Us on Social Media:

     Facebook
     Instagram
     LinkedIn 

SOURCE Legal-Bay LLC

(CSE: URAI / OTC: URAIF / FSE: 3QG0)
[email protected]

Highlights

• Inturai’s DomeCommand platform selected in a highly selective first wave from over 450 applicants.
• Development advances with the European Defence Tech Hub and the Republic of Singapore Air Force.
• Three-month fast-track commercialisation program opens pathways to milestone funding, testbeds and defence networks.

VANCOUVER, BC, July 29, 2026 — Inturai Ventures Corp. (the “Company”) (CSE: URAI) (OTC: URAIF) (FSE: 3QG0) is pleased to announce that DomeCommand, the drone-swarm command-and-control platform under the Company’s previously announced proposed acquisition, has been selected in a highly selective first wave from over 450 applicants for SDTH 2026, a three-month fast-track defence commercialisation program in Singapore.

Development through the program will be carried out in partnership with the European Defence Tech Hub and the Republic of Singapore Air Force, with a partner network that includes DSTA, DSO National Laboratories, ST Engineering, NUS Enterprise, TUM Venture Labs, Accenture, Cognition and Shield AI. Over three months, selected platforms are prototyped, tested, and advanced toward procurement-ready form, with direct pathways to incubation, milestone funding, testbeds and senior defence networks. The program culminates in the main SDTH event on September 25 to 27, 2026.

DomeCommand will develop within Little Red Dome, the program’s layered counter-drone mission built to detect, decide, and defeat drone swarms and advanced aerial threats. Counter-drone spending focuses on sensors and effectors, while the command-and-control (C2) layer that fuses detection data into coordinated responses remains thinly served. Paired with Inturai’s defence-grade spatial sensing, which detects threats in contested and complex environments where cameras fail, the Company holds a rare greenfield position outside the saturated, capital-intensive drone hardware market.

Ed Clarke, CEO of Inturai Ventures Corp., commented:

“Developing DomeCommand alongside the European Defence Tech Hub and the Republic of Singapore Air Force compresses years of defence market entry into months. The C2 layer is the gap in the counter-drone market, and this program fast-tracks it toward the operators who will buy it. We intend to convert this into pilot deployments across defence and critical-infrastructure markets.”

The same capability protects national critical infrastructure. Airports, power grids, ports, and correctional facilities face growing drone incursions, and operators need to detect, decide and respond in seconds. The Company’s combined sensing and C2 platform is designed to deliver that response as one system, giving Inturai two adjacent markets from a single platform. Further updates on the acquisition and the program will be provided as milestones are reached.

On behalf of the Board of Directors

About Inturai Ventures

Inturai Ventures is advancing intelligent environments with cutting-edge AI technologies, transforming industries such as healthcare, military, smart homes, and industrial applications. For more information, visit www.inturai.com. For investor inquiries:

On behalf of the Board of Directors

Ed Clarke, CEO
Inturai Ventures Corp.
Email: [email protected]
Phone: (+1) 604 339-0339

This document contains certain forward-looking statements that are based on assumptions as of the date of this news release. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company’s control. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE INTURAI VENTURES CORP.

MELBOURNE, Australia and BOSTON, July 28, 2026 — Melbourne- and Boston-based medical device company Navi Medical Technologies has closed a $A6.8 million capital raise to commercialise its breakthrough paediatric vascular access technology in the United States.

The raise follows US FDA 510(k) clearance and the commencement of clinical evaluations of the company’s Neonav® technology at two leading US children’s hospitals.

The round was led by healthcare venture capital firm KP Rx, which invested $A4 million. Existing investor Innovation Victoria was joined by New Zealand- and Melbourne-based Pacific Channel.

The capital will be used to expand manufacturing, build the company’s US commercial team and support the launch of the Neonav® into leading children’s hospitals.

Commercial sales are expected to commence this year.

The Neonav® addresses one of the most challenging procedures in neonatal and paediatric intensive care – the accurate placement and management of central venous access devices used to deliver nutrition, fluids and medications.

Alex Newton, Chief Executive Officer of Navi Medical Technologies, said: “Neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients.”

The misplacement or migration of a catheter can have serious consequences for patients, including damage to the heart or surrounding tissues, which can sometimes be fatal, especially in tiny patients.

ECG-guided catheter placement is standard practice for adult patients in the US, neonatal and paediatric clinicians rely heavily on X-ray confirmation as existing technologies do not adequately address the unique challenges of the smallest patients.

The Neonav® combines real-time ECG-guided catheter placement with ongoing catheter migration surveillance, enabling clinicians to reassess catheter position throughout the use of the catheter – a capability that extends beyond conventional ECG tip location systems and has the potential to improve patient safety while reducing repeat imaging.

The investment follows a defining period for the company. In 2025, the Neonav® received US FDA 510(k) clearance, enabling Navi to enter the world’s largest healthcare market. Clinical evaluations have since commenced with leading US children’s hospitals.

In 2026, Navi received an expanded US FDA indication for use, extending Neonav®’s cleared applications to include additional vascular access procedures for umbilical venous catheters, further strengthening the platform’s commercial opportunity. The Neonav® now has the broadest indications for use for paediatric and neonatal vascular access covering all central venous access devices and procedures.

Hashan De Silva, Partner at KP Rx, said Navi had reached an important commercial inflection point. “Navi has developed a genuinely differentiated technology addressing a significant unmet clinical need. The company has demonstrated exceptional execution – from product development to FDA clearance and early engagement with leading US children’s hospitals. We believe the Neonav® has the potential to become an important new technology in neonatal and paediatric vascular access, and we’re excited to support the team as they scale.”

Alex Newton, Chief Executive Officer of Navi Medical Technologies, said the funding would accelerate the company’s transition from clinical validation to commercialisation.

“For decades, neonatal and paediatric clinicians have relied on technologies that were never designed for their smallest patients. The Neonav® was built to change that.

“This investment allows us to scale manufacturing, grow our US team and partner with leading children’s hospitals as we work to establish a new standard of care in neonatal and paediatric vascular access.”

Rod Bristow, CEO of Innovation Victoria, said the investment demonstrated the global potential of Australian medical technology innovation.

“What stands out about Navi is the quality of both the innovation and the execution. The team has consistently delivered on major milestones and demonstrated that a Victorian company can develop world-leading healthcare technology with global relevance.

“Their progress over the past year has been exceptional, and we’re pleased to continue supporting their growth as they take this technology to more hospitals and more patients around the world.”

Roland Toder, General Partner at Pacific Channel, said Navi’s combination of clinical innovation and commercial execution made it a compelling investment opportunity.

“Navi has developed a highly differentiated technology that addresses a significant unmet need in neonatal and paediatric critical care.

“The team has impressively navigated a demanding clinical and regulatory pathway, achieving important milestones that position the company strongly for future growth and reinforce its potential to establish itself as a global leader in this category.

“We’re excited to support Navi as it enters the next stage of commercial growth in the United States.”

About: Navi Medical Technologies

Founded in Melbourne, Navi Medical Technologies develops next-generation vascular access technologies for neonatal and paediatric care. The company has operations in Australia and the United States and expects to commence US commercial sales in 2026.

SOURCE Navi Medical Technologies

Finanzierung zur Deckung der rasch steigenden kommerziellen Nachfrage nach der firmeneigenen ClarosTechUV™-Technologie und zur Unterstützung des Ausbaus des mobilen Labors ClarosLabs™, nachdem bahnbrechende Ergebnisse bei der PFAS-Grundwassersanierung erzielt und die weltweiten PFAS-Vorschriften verschärft wurden.

MINNEAPOLIS, 29. Juli 2026 — Claros Technologies, Inc. (Claros), ein weltweit führender Anbieter von Lösungen zur Zersetzung und Analyse von PFAS – Per- und Polyfluoralkylsubstanzen, allgemein bekannt als „Forever Chemicals” – gab heute den erfolgreichen Abschluss einer Serie-B-Finanzierungsrunde in Höhe von 55 Millionen US-Dollar bekannt, einschließlich der zuvor angekündigten Finanzierung durch Wandelanleihen des Unternehmens. Die Finanzierung wird dazu beitragen, die weltweite Markteinführung des firmeneigenen ClarosTechUV™-PFAS-Abbausystems zu beschleunigen, ClarosLabs™ auszubauen, die Produktion und den Betrieb zu stärken sowie die wachsende Nachfrage von Industrieunternehmen, Sanierungsfirmen, Versorgungsunternehmen und Behörden zu bedienen, die nach einer dauerhaften PFAS-Zersetzung und fortschrittlichen Analyselösungen suchen.

Die Serie-B-Finanzierungsrunde wurde von Treehouse Family Capital LLC angeführt, unter Beteiligung von Daikin America, Inc., Veralto, der Bush Foundation, Nord Asset Management, und der Saint Paul & Minnesota Foundation, sowie mit fortgesetzter Unterstützung durch bestehende Investoren. An der Finanzierungsrunde beteiligte sich eine vielfältige Gruppe institutioneller und strategischer Investoren aus den Bereichen Industrie, Umwelt und Technologie, was die breite Anerkennung der geschäftlichen Dynamik von Claros, seiner einzigartigen Technologieplattform und der bedeutenden globalen Chancen widerspiegelt, die sich im Zusammenhang mit der dauerhaften PFAS-Zersetzung und entsprechenden Analyselösungen ergeben.

Die Technologie von Claros ermöglicht den weiteren Einsatz von PFAS in kritischen Anwendungen in Schlüsselbranchen wie der Halbleiterfertigung, der Luft- und Raumfahrt, der Pharmaindustrie und dem Gesundheitswesen und sorgt gleichzeitig für die Zersetzung von PFAS im industriellen Maßstab. Das Ergebnis ist eine Lösung, die sowohl die Innovation als auch den Umweltschutz vorantreibt.

Die Finanzierung dient der Erweiterung der Produktionskapazitäten, zusätzlichen kommerziellen Einsätzen in Nordamerika, Europa und Asien, der weiteren Produktentwicklung, dem Ausbau von ClarosLabs™, strategischen Neueinstellungen in den Bereichen Technik und Vertrieb sowie laufenden Investitionen in den Kundensupport und die Anwendungsentwicklung. Die Finanzierung versetzt Claros in die Lage, der steigenden weltweiten Nachfrage gerecht zu werden, da Industrie und Regierungen zunehmend von der PFAS-Verwaltung auf Technologien zur dauerhaften Zersetzung umstellen.

Michelle Bellanca, CEO und Mitgründerin von Claros Technologies, hob die Bedeutung der jüngsten positiven Entwicklung des Unternehmens sowie des zur Unterstützung der nächsten Wachstumsphase gesicherten Kapitals hervor:

„Im vergangenen Jahr hat Claros den Schritt von der bahnbrechenden Technologie zur erfolgreichen kommerziellen Umsetzung geschafft. Unsere Zusammenarbeit mit großen Industrieunternehmen hat gezeigt, dass die dauerhafte Zerstörung aller anvisierten PFAS-Verbindungen im kommerziellen Maßstab zuverlässig, effizient und kostengünstig durchgeführt werden kann, während unsere jüngsten Ergebnisse bei der Grundwassersanierung belegen, dass dieselbe Technologie auch bei komplexen Umweltanwendungen außergewöhnlich gute Leistungen erbringt. In Verbindung mit der rasanten Entwicklung und Umsetzung von PFAS-Vorschriften weltweit haben diese Meilensteine unsere Möglichkeiten grundlegend erweitert. Diese Finanzierung verschafft uns die Mittel, um die kommerzielle Einführung weltweit zu beschleunigen, unsere Technologie weiterzuentwickeln und unseren Kunden dabei zu helfen, eine der größten ökologischen Herausforderungen der Welt zu bewältigen.”

Jack Cogen, Geschäftsführer von Treehouse Family Capital LLC, fügte hinzu:

„Die spannendsten Technologieunternehmen erreichen irgendwann einen Wendepunkt, an dem es nicht mehr darum geht, ob die Technologie funktioniert, sondern darum, wie schnell sie in großem Maßstab eingesetzt werden kann. Wir glauben, dass Claros diesen Punkt erreicht hat. Claros hat bewiesen, dass seine Technologie unter realen kommerziellen Bedingungen effektiv ist. Claros hat eine integrierte Plattform entwickelt, die die PFAS-Zersetzung mit Analysedienstleistungen verbindet, und baut diese nun genau zum richtigen Zeitpunkt kommerziell aus. Angesichts der weltweit zunehmenden Regulierungsdynamik sehen wir die Chance, zum Aufbau eines der maßgeblichen Umwelttechnologieunternehmen des nächsten Jahrzehnts und darüber hinaus beizutragen.”

Claros hat mehrere wichtige kommerzielle Meilensteine erreicht, die ClarosTechUV™ als führende, praxiserprobte Technologie zur PFAS-Zersetzung etabliert haben. Im Dezember 2025 führte das Unternehmen in Zusammenarbeit mit Daikin America eine der weltweit größten Vor-Ort-Demonstrationen zur PFAS-Zersetzung von industriellem Prozesswasser erfolgreich durch und erzielte dabei eine Zersetzungsrate von über 99,99 % bei lang-, kurz- und ultrakurzkettigen PFAS-Verbindungen. Im April 2026 wies Claros bei Anwendungen zur Grundwassersanierung eine Zerstörung der Ziel-PFAS-Verbindungen von ≥99,99 % nach, wobei ein Konzentrat aus etwa einer Million Gallonen (3,8 Millionen Litern) Grundwasser verwendet wurde. Damit wurde die Skalierbarkeit der Technologie sowohl für industrielle Fertigungs- als auch für Umweltsanierungsanwendungen bestätigt.

Zusammen markieren diese Meilensteine den Übergang von Claros von der kommerziellen Validierung hin zur breiten Markteinführung und versetzen das Unternehmen in die Lage, seine integrierte Plattform für die PFAS-Zersetzung und Analysedienstleistungen weltweit in den Bereichen industrielle Fertigung, Umweltsanierung und Einhaltung gesetzlicher Vorschriften kommerziell anzubieten.

Die Finanzierung erfolgt vor dem Hintergrund, dass sich das weltweite regulatorische Umfeld im Zusammenhang mit PFAS weiterhin rasant weiterentwickelt. In Europa treiben die politischen Entscheidungsträger im Rahmen der vorgeschlagenen REACH-Verordnung umfassende PFAS-Beschränkungen voran und prüfen gleichzeitig branchenspezifische Ausnahmeregelungen für wesentliche Verwendungszwecke. In den Vereinigten Staaten verschärfen Bundes- und Landesbehörden weiterhin die Trinkwassernormen, die Auflagen für Industrieeinleitungen und die Sanierungsmaßnahmen. Da diese behördlichen Anforderungen immer umfassender werden, suchen Unternehmen zunehmend nicht nur nach Technologien zur dauerhaften PFAS-Zersetzung, sondern auch nach fortschrittlichen Analysedienstleistungen, mit denen sich PFAS präzise nachweisen, quantifizieren und dokumentieren lassen, um die Einhaltung der Vorschriften zu gewährleisten. Zusammen sorgen diese sich verstärkenden Trends für eine steigende Nachfrage sowohl nach der ClarosTechUV™-Technologie zur PFAS-Zersetzung als auch nach ClarosLabs™, dem Angebot des Unternehmens an PFAS-Analysedienstleistungen.

Informationen zu Claros Technologies

Claros Technologies wurde 2018 gegründet, hat seinen Sitz in Minneapolis im US-Bundesstaat Minnesota und ist ein weltweit führendes Unternehmen im Bereich der PFAS-Sanierung mit zwei Kerngeschäftsbereichen. Der Geschäftsbereich ClarosTech™ konzentriert sich ausschließlich auf die dauerhafte Zersetzung von PFAS und bietet kostengünstige, durchsatzstarke, skalierbare und einsatzbereite Systeme an, mit denen lang-, kurz- und ultrakurzketten PFAS-Verbindungen zerstört werden können. ClarosLabs™, der nach ISO/IEC 17025:2017 akkreditierte Analysebereich des Unternehmens, ist ein führendes kommerzielles Labor, das sich ausschließlich auf den Nachweis, die Quantifizierung und die Expositionsbewertung von PFAS spezialisiert hat. Claros hat es sich zur Aufgabe gemacht, PFAS aus der Umwelt zu entfernen. Claros macht den Begriff „ewige Chemikalien” überflüssig und beseitigt PFAS ein für alle Mal.

Medienkontakt:
Kari Finkler
[email protected]

Financement destiné à répondre à la demande commerciale en forte croissance pour la technologie exclusive ClarosTechUV™ et à soutenir l’expansion du laboratoire mobile ClarosLabs™, à la suite des résultats révolutionnaires obtenus en matière d’assainissement des eaux souterraines contaminées par les PFAS et compte tenu du durcissement des réglementations mondiales concernant ces composés chimiques.

MINNEAPOLIS, 29 juillet 2026 — Claros Technologies, Inc. (Claros), leader mondial des solutions de destruction et d’analyse des PFAS (substances per- et polyfluoroalkylées), communément appelées « produits chimiques éternels », a annoncé aujourd’hui la clôture réussie d’un tour de table de série B de 55 millions de dollars, incluant le financement par obligations convertibles précédemment annoncé par la société. Ce financement permettra d’accélérer la commercialisation mondiale du système exclusif de destruction des PFAS ClarosTechUV™, de développer ClarosLabs™, de renforcer les capacités de production et les opérations et de répondre à la demande croissante des industriels, des entreprises de dépollution, des services publics et des organismes publics à la recherche de solutions de destruction définitive des PFAS et d’analyses pointues.

Le tour de table de série B a été dirigé par Treehouse Family Capital LLC, avec la participation de Daikin America, Inc., Veralto, la Fondation Bush, Nord Asset Management, la Fondation Saint Paul & Minnesota et avec le soutien continu des investisseurs existants. Ce tour de table a réuni un groupe diversifié d’investisseurs institutionnels et stratégiques issus des secteurs de l’industrie, de l’environnement et des technologies, signe de l’intérêt incontestable suscité par la dynamique commerciale de Claros, par sa plateforme technologique différenciée et par l’important potentiel mondial concernant la destruction définitive des PFAS et les solutions d’analyse.

La technologie de Claros permet de poursuivre l’utilisation des PFAS dans des applications critiques au sein de secteurs clés, notamment la fabrication de semi-conducteurs, l’aérospatiale, l’industrie pharmaceutique et le secteur de la santé, tout en permettant la destruction des PFAS à l’échelle industrielle. Il en résulte une solution favorisant à la fois l’innovation et la protection de l’environnement.

Ce financement va permettre de renforcer les capacités de production, de multiplier les déploiements commerciaux en Amérique du Nord, en Europe et en Asie, de poursuivre le développement de produits, d’élargir les applications de ClarosLabs™, de procéder à des recrutements stratégiques dans les domaines de l’ingénierie et des opérations commerciales et de continuer à investir dans le service client et le développement d’applications. Ce financement permet à Claros de répondre à une demande mondiale en forte croissance, alors que les industries et les gouvernements s’orientent de plus en plus vers des technologies de destruction définitive des PFAS, plutôt que se contenter de gérer ces substances.

Michelle Bellanca, directrice générale et cofondatrice de Claros Technologies, a souligné l’importance de la dynamique récente de l’entreprise et des fonds levés pour soutenir la prochaine phase de sa croissance :

« Au cours de l’année écoulée, Claros a franchi le cap qui sépare une technologie révolutionnaire d’une réalité commerciale rentable. Notre collaboration avec de grands fabricants industriels a montré que la destruction définitive de toutes les espèces de PFAS ciblées peut être mise en œuvre de manière fiable, efficace et rentable à l’échelle commerciale, tandis que nos récents résultats en matière d’assainissement des eaux souterraines ont montré que cette même technologie offre des performances exceptionnelles dans des applications environnementales complexes. Conjuguées à l’évolution rapide et à la mise en œuvre des réglementations relatives aux PFAS à travers le monde, ces avancées ont considérablement élargi nos perspectives. Ce financement nous apporte les moyens d’accélérer nos déploiements commerciaux à l’échelle mondiale, de continuer le développement de notre technologie et d’aider nos clients à relever l’un des défis environnementaux les plus importants au monde. »

Jack Cogen, directeur de Treehouse Family Capital LLC, a ajouté :

« Les entreprises technologiques les plus prometteuses finissent par atteindre un point d’inflexion où la question n’est plus de savoir si la technologie fonctionne, mais à quelle rapidité elle peut être déployée à grande échelle. Nous pensons que Claros a atteint ce stade. Claros a démontré l’efficacité de sa technologie dans des conditions commerciales réelles. Claros a créé une plateforme intégrée qui associe la destruction des PFAS à des services d’analyse et se développe commercialement au moment le plus opportun. Alors que la dynamique réglementaire s’accélère à l’échelle mondiale, nous y voyons une opportunité de contribuer à la création de l’une des entreprises phares du secteur des technologies environnementales pour la prochaine décennie et au-delà. »

Claros a franchi plusieurs étapes commerciales décisives qui ont permis à ClarosTechUV™ de s’imposer comme la technologie de destruction des PFAS de référence qui a fait ses preuves sur le terrain. En décembre 2025, l’entreprise, en partenariat avec Daikin America, a effectué l’une des plus grandes démonstrations au monde de destruction sur site de PFAS présents dans les eaux de process industrielles, en atteignant un taux de destruction supérieur à 99,99 % pour les composés PFAS à chaîne longue, courte et ultra-courte. En avril 2026, Claros a démontré une destruction ≥  à 99,99 % des composés PFAS ciblés dans le cadre d’applications d’assainissement des eaux souterraines, à l’aide d’un concentré issu d’environ un million de gallons (3,8 millions de litres) d’eau souterraine, validant ainsi l’évolutivité de la technologie tant pour les applications de fabrication industrielle que pour celles d’assainissement environnemental.

Ensemble, ces étapes marquantes témoignent de la transition de Claros, qui passe de la validation commerciale à un déploiement commercial à grande échelle, permettant ainsi à l’entreprise de proposer sa plateforme intégrée de services d’analyse et de destruction des PFAS sur les marchés mondiaux de la fabrication industrielle, de la dépollution environnementale et de la conformité réglementaire.

Ce financement intervient alors que le cadre réglementaire mondial relatif aux PFAS évolue rapidement. En Europe, les décideurs politiques mettent en place des restrictions générales concernant les PFAS dans le cadre du projet de règlement REACH, tout en évaluant des dérogations sectorielles pour les utilisations essentielles. Aux États-Unis, les agences fédérales et étatiques continuent de renforcer les normes relatives à l’eau potable, ainsi que les exigences en matière de rejets industriels et les programmes d’assainissement. À mesure que ces exigences réglementaires deviennent encore plus précises, les organisations recherchent de plus en plus non seulement des technologies permettant la destruction définitive des PFAS, mais aussi des services d’analyse de pointe capables de détecter, de quantifier et de documenter avec précision les PFAS afin de garantir la conformité réglementaire. Ensemble, ces tendances convergentes stimulent la demande tant pour la technologie de destruction des PFAS ClarosTechUV™ que pour ClarosLabs™, l’offre de services d’analyse des PFAS de l’entreprise.

À propos de Claros Technologies

Fondée en 2018 et implantée aux États-Unis, à Minneapolis, dans le Minnesota, Claros Technologies est un leader mondial dans l’atténuation des PFAS, avec deux divisions principales La division ClarosTech™ se concentre exclusivement sur la destruction permanente des PFAS, en proposant des systèmes abordables, à haut débit, évolutifs et prêts pour le terrain, qui détruisent les composés à chaîne longue, courte et ultra-courte. ClarosLabs™, la division analytique de l’entreprise, accréditée ISO/IEC 17025:2017, est un laboratoire commercial de premier plan qui se consacre uniquement à la détection des PFAS, à leur quantification et à l’évaluation de l’exposition. Claros poursuit la mission d’éliminer les PFAS de l’environnement. Claros veut éliminer le caractère « éternel » des « substances chimiques éternelles » et détruire définitivement les PFAS.

Contact presse :
Kari Finkler
[email protected]